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Abstract
Background—Chronic lung diseases are increasingly recognized complications of verticallyacquired HIV among adolescents in sub-Saharan Africa and may manifest with hypoxia or
tachypnea. We sought to determine the prevalence of and risk factors for hypoxia and tachypnea
among adolescents with vertically-acquired HIV in Nairobi, Kenya.
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Methods—We performed a cross-sectional analysis of 258 adolescents with vertically-acquired
HIV who were initiating care at the Coptic Hope Center for Infectious Diseases. Adolescents with
documented pneumonia were excluded. Hypoxia was defined as resting oxygen saturation ≤92%,
and tachypnea was based on the 99th percentile of age-appropriate respiratory rates. Logistic
regression models adjusted for demographics and HIV severity estimated odds ratios (ORs) for
risk of hypoxia and tachypnea associated with potential risk factors.
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Results—Overall, 11% of adolescents had hypoxia and 55% had tachypnea. Advanced HIV
(adjusted OR [aOR] 2.41) and low CD4 (aOR 1.74) were associated with greater hypoxia risk, but
confidence intervals (CI) were wide and included the null (95% CI 0.93–6.23 and 0.69–4.39,
respectively). Low CD4 (aOR 2.45, 95% CI 1.39–4.32), current ART use (aOR 0.48, 95% CI
0.27–0.86) and stunted growth (aOR 3.46, 95% CI 1.94–6.18) were associated with altered
tachypnea risk.
Conclusions—Hypoxia and tachypnea are common among adolescents with vertically-acquired
HIV. There was a suggestion that advanced HIV and low CD4 were associated with greater
hypoxia risk. Low CD4, lack of ART use and stunted growth are risk factors for tachypnea. Our
findings highlight the chronic lung disease burden in this population and may inform diagnostic
algorithms.
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INTRODUCTION
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Over 3 million HIV-infected children and adolescents live in sub-Saharan Africa, and nearly
all of them acquired HIV through vertical transmission.1 Lung diseases, such as lymphocytic
interstitial pneumonia, recurrent pneumonia, tuberculosis and bronchiectasis, are welldescribed among HIV-infected children <10 years old in sub-Saharan Africa2 and may also
affect adolescents. The spectrum of pulmonary complications among HIV-infected
adolescents in these settings additionally includes the chronic lung diseases: obliterative
bronchiolitis, pulmonary hypertension and asthma.3 However, limited availability of chest
radiography and lung function testing hinders definitive diagnosis.4
Respiratory abnormalities, such as hypoxia and tachypnea, are often manifestations of lung
disease,5–7 and their presence may aid in identifying HIV-infected adolescents with chronic
lung diseases. Among adolescents with vertically-acquired HIV in Zimbabwe who had no
acute respiratory symptoms, 13% had hypoxia at rest and 28% were tachypneic.3 Over 40%
had lung function abnormalities or radiographic evidence of chronic lung disease. However,
risk factors for chronic lung diseases and their manifestations are not well-defined among
adolescents with vertically-acquired HIV in resource-limited settings. As oxygen saturation
and respiratory rate are frequently measured during routine clinic visits, we conducted this
study to determine: a) the prevalence of hypoxia and tachypnea among adolescents with
vertically-acquired HIV in Nairobi, Kenya; and b) risk factors for hypoxia and tachypnea
among these adolescents.
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METHODS
Study design and population
We performed a cross-sectional analysis of data from adolescents with vertically-acquired
HIV who were initiating care at the Coptic Hope Center for Infectious Diseases in Nairobi
from 2004 to 2013. The Hope Center provides comprehensive care to HIV-infected
individuals according to Kenyan guidelines.8 Data were abstracted from electronic research
Pediatr Infect Dis J. Author manuscript; available in PMC 2018 April 01.
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records populated with information from initial clinic visits. University of Washington and
Kenyatta National Hospital Institutional Review Boards approved this study.
We restricted eligibility age to 10–16.9 years old because data supporting vertical HIV
transmission, including documentation of HIV risk factors and maternal/sibling HIV status,
were systematically collected for this age group. To identify baseline respiratory
abnormalities, we excluded adolescents with documented pneumonia at initial clinic visits.
Of 258 eligible adolescents, 56 did not have recorded oxygen saturation. We retained these
adolescents in our overall cohort as characteristics of adolescents with and without
documented oxygen saturation were similar.
Respiratory abnormalities

Author Manuscript

We defined hypoxia as resting oxygen saturation ≤92% by pulse oximetry.9 As normal
respiratory rates vary by age during adolescence, we defined tachypnea as a respiratory rate
greater than the 99th percentile of age-appropriate values (Table 1).10 Few published
guidelines define hypoxia and tachypnea at Nairobi’s altitude of ~1,700 meters;9 therefore,
to minimize the likelihood that our outcome definitions misclassified adolescents with
normal oxygen saturation and respiratory rate into abnormal groups, we also considered
more conservative cutoffs for oxygen saturation (≤90%) and respiratory rate (Table 1).
Potential risk factors
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Baseline demographics included age and gender. Stunted growth and malnutrition were
defined as height-for-age and body mass index (BMI)-for-age Z-scores < −2, respectively.11
HIV severity was categorized per World Health Organization (WHO) clinical staging
criteria. Advanced HIV was defined as WHO HIV stages 3 and 4. Current antiretroviral
therapy (ART) and co-trimoxazole use were based on self-report. CD4 count (cells/μL) was
measured within 30 days of care initiation. We defined low CD4 as <200 cells/μL. Indoor
biofuel burning was based on self-reported use of wood, charcoal or kerosene as energy
sources within the adolescent’s home.
Statistical analysis
To determine independent associations of each of the covariates in Tables 2 and 3 with
hypoxia and tachypnea, we generated multivariable logistic regression models. Final models
included age (continuous) and gender to account for potential confounding. We also adjusted
for WHO HIV stage to minimize potential selection bias, as HIV-infected adolescents who
are ill may be more likely to seek medical care.12 We repeated these analyses using
conservative cutoffs for hypoxia and tachypnea.
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All analyses were performed using Stata 13 (Stata Corp., College Station, TX).

RESULTS
Cohort characteristics
Most adolescents were at the lower end of included ages (51% were 10–12.9 years old);
49% were male, 40% had stunted growth and 19% were malnourished. Overall, 34% had

Pediatr Infect Dis J. Author manuscript; available in PMC 2018 April 01.
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WHO HIV stage 3/4, 28% reported current ART use and 51% reported taking cotrimoxazole. Median CD4 was 326 cells/μL (interquartile range 125–549), and 33% had
CD4 <200 cells/μL. A substantial proportion of data was missing for indoor biofuel burning
exposure; among adolescents for whom data were available, 53% reported exposure.
Overall, 22 of 202 adolescents (11%) had hypoxia (oxygen saturation ≤92%), and 143 of
258 (55%) had tachypnea (Table 1). When applying conservative outcome definitions, 13
(6%) had hypoxia and 60 (23%) had tachypnea.
Risk factors for hypoxia

Author Manuscript

On average, adolescents with hypoxia were younger than those without hypoxia (per one
year, adjusted odds ratio [aOR] 0.81, 95% confidence interval [CI] 0.66–0.99; Table 2).
Advanced HIV was associated with greater risk for hypoxia: 55% of adolescents with
hypoxia but only 31% of those without hypoxia had advanced HIV (aOR 2.41, 95% CI
0.93–6.23). Ten of the 22 adolescents with hypoxia (45%) had low CD4, in contrast to 31%
of those without hypoxia. This association persisted after adjustment for age, gender and
WHO HIV stage (aOR 1.74), but, as with advanced HIV, the small number of subjects led to
a statistically imprecise result (95% CI 0.69–4.39). Adolescents with hypoxia were more
likely to report indoor biofuel burning; however, the extent of missing data prohibited any
meaningful conclusions to be drawn.
In sensitivity analyses, using oxygen saturation ≤90% as the outcome, the association with
advanced HIV was further attenuated (aOR 1.49, 95% CI 0.65–4.45), while the association
with low CD4 was not substantially changed (aOR 1.96, 95% CI 0.63–6.05). The association
with younger age remained similar (aOR 0.68, 95% CI 0.53–0.87).
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Risk factors for tachypnea
Adolescents with tachypnea were younger on average than those without tachypnea (per one
year, aOR 0.80, 95% CI 0.70–0.91; Table 3). Of adolescents with tachypnea, 51% had
stunted growth compared to 26% of those without tachypnea (aOR 3.46, 95% CI 1.94–6.18).
The prevalence of advanced HIV was 34% among those with and without tachypnea. Only
22% with tachypnea were using ART compared to 36% of those without tachypnea (aOR
0.48, 95% CI 0.27–0.86), and a greater proportion of adolescents with tachypnea had low
CD4 (40% vs 25%; aOR 2.45, 95% CI 1.39–4.32). Exposure to indoor biofuel burning was
more prevalent among those with tachypnea. Additionally adjusting these models for stunted
growth did not appreciably alter associations (data not shown).
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When using conservative cut-offs for tachypnea, associations with low CD4 (aOR 2.41, 95%
CI 1.31–4.44), current ART use (aOR 0.26, 95% CI 0.11–0.62) and stunted growth (aOR
3.78, 95% CI 1.98–7.22) were largely unchanged, but the association with age was
diminished (aOR 0.95, 95% CI 0.82–1.10).

DISCUSSION
Hypoxia and tachypnea were common in this cohort of adolescents with vertically-acquired
HIV in Nairobi. There was a suggestion that advanced HIV and low CD4 were associated

Pediatr Infect Dis J. Author manuscript; available in PMC 2018 April 01.
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with greater risk of hypoxia. Low CD4, lack of ART and stunted growth were risk factors
for tachypnea. These respiratory abnormalities may have clinically relevant implications. In
a study of HIV-infected adolescents in Malawi, chronic lung disease phenotypes were
characterized as hypoxia- or cough-predominant.7 Although pathologic correlates were not
available in that study or in ours, specific combinations of routinely ascertained signs and
symptoms may contribute to future clinical algorithms for identifying adolescents with
chronic lung diseases in resource-limited settings. Most risk factors identified in our study
are modifiable and may be amenable targets for mitigating the burden of chronic lung
diseases.
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HIV-related immunosuppression was associated with hypoxia and tachypnea. While WHO
HIV stages 3/4 encompass prior severe and AIDS-defining illnesses, low current CD4
imparts contemporaneous risk of opportunistic infections and non-infectious
comorbidities.13 Current CD4 may reflect immunosuppression that has persisted for weeks,
months or years. Longstanding HIV infection in children during critical periods of immune
system and organ development may influence organ injury and increase risk of chronic lung
diseases of the parenchyma, airways and vasculature,2,3,7,14 potentially impairing gas
exchange.5 Concurrently, pulmonary infections may trigger local inflammation and resultant
destructive lung lesions. Though it is unclear from this cross-sectional study if severe
immunosuppression indeed predisposes to hypoxia and tachypnea, and whether it is because
of immune dysfunction or prior pulmonary infections, our findings suggest that hypoxia and
tachypnea in adolescents with advanced HIV or low CD4 are common and may warrant
further pulmonary evaluation where available.
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We also detected an association of current ART use with lower tachypnea risk. ART scale-up
has led to dramatic declines in morbidity and mortality, but <40% of eligible HIV-infected
children and adolescents access ART in sub-Saharan Africa.1 Further, ART initiation at
advanced HIV or lower CD4 may attenuate this observed risk reduction, as immune function
defects and pulmonary parenchymal damage may not be completely reversible.3,14 The
association of ART with tachypnea suggests that immune modulation and pulmonary
infection mitigation by ART has important implications for pulmonary pathophysiology,
underscoring potential benefits of early, universal ART.
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We also found that stunted growth was a strong predictor of tachypnea. In our cohort, 40%
of adolescents had stunted growth, which is reported in as many as 50% of HIV-infected
children and is linked with advanced HIV.15 Adolescents with stunted growth who acquired
HIV vertically may have impaired lung development, as lung development is physiologically
associated with growth velocity and height attainment. If adequate growth attainment does
not occur by five years of age, impaired lung function may persist into adulthood,16 raising
the concern that sequelae of stunted growth identified during adolescence may be
irreversible. Stunted growth reflects long-term exposures and may capture elements of
socioeconomic status, such as wealth, education and environmental conditions.17
Finally, we found that younger age was associated with greater hypoxia and tachypnea risk,
potentially suggesting a survivor bias. In sub-Saharan Africa, adolescents with delayed
diagnosis of vertically-acquired HIV often present at advanced HIV stages12 with stunted

Pediatr Infect Dis J. Author manuscript; available in PMC 2018 April 01.
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growth, frequent infections and respiratory abnormalities.18 These “slow progressors”
comprise up to 36% of infants with vertically-acquired HIV and may survive a median 16
years without ART.19 As adolescents with untreated HIV have a high mortality risk,12 many
with undiagnosed, advanced HIV will have died, some with respiratory abnormalities, prior
to seeking care. However, we pose this hypothesis cautiously as the association with age was
attenuated when data were analyzed using conservative cutoffs for tachypnea (though the
association remained for hypoxia).
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No consensus guidelines designate cutoffs for abnormal oxygen saturation or respiratory rate
at Nairobi’s moderate altitude. However, altitude-specific models estimate a hypoxia
threshold of 95% oxygen saturation,9 indicating that this altitude is unlikely to impact
hypoxia prevalence. We observed tachypnea among 55% of adolescents compared to 28% in
the Zimbabwean study. Applying that study’s cut-off (>25 breaths per minute) in our cohort
yields a 42% tachypnea prevalence. Though unlikely, it remains possible that Nairobi’s
altitude accounts for a fraction of our observed tachypnea prevalence.
Our study has several other limitations. First, the sample size was relatively small,
representing only adolescents initiating care at the Hope Center who met criteria for
vertically-acquired HIV. Second, vertically-acquired HIV criteria were based on self-report,
which may have resulted in some misclassification. However, the median age for sexual
debut in Kenya is 17–24 years old,20 supporting that the majority of adolescents in our
cohort acquired HIV vertically. Third, the substantial proportion of missing data for indoor
biofuel burning limited our ability to draw conclusions about associations regarding this
exposure. Finally, despite controlling for potential confounding factors, there may still be
residual confounding of associations.
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In conclusion, hypoxia and tachypnea were common among adolescents with verticallyacquired HIV. The association of advanced HIV, low CD4 and lack of ART with greater risk
of hypoxia or tachypnea suggests that sequelae of uncontrolled HIV may contribute to
pulmonary injury. Stunted growth, especially in HIV, may impact lung development. As the
prevalence of adolescents with vertically-acquired HIV in sub-Saharan Africa is not
anticipated to decline for another decade,19 further studies are needed to understand
implications of these respiratory abnormalities and to determine whether they can be utilized
systematically to identify chronic lung diseases among HIV-infected adolescents in
resource-limited settings.
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0.52 (0.30 – 0.90)

Referent

2.01 (1.17 – 3.47)

Referent

1.00 (0.59 – 1.68)

Referent

1.31 (0.68 – 2.54)

Referent

3.07 (1.78 – 5.30)

Referent

1.04 (0.64 – 1.70)

--

--

--

0.81 (0.72 – 0.92)

Crude OR (95% CI)

0.48 (0.27 – 0.86)

Referent

2.45 (1.39 – 4.32)

Referent

0.96 (0.56 – 1.65)¥

Referent

1.24 (0.62 – 2.50)

Referent

3.46 (1.94 – 6.18)

Referent

0.93 (0.55 – 1.56)§

--

--

--

0.80 (0.70 – 0.91)‡

aOR – adjusted for age, gender and WHO HIV clinical stage (95% CI)

Demographic and clinical characteristics among adolescents with and without tachypnea (n = 258)

Author Manuscript

Table 3
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18
99

Missing

--

41%

59%

Only adjusted for age and WHO HIV clinical stage

Only adjusted for gender and WHO HIV clinical stage

Only adjusted for age and gender

¥

§

‡

26

50%

72

No

50%

78%

%

71

111

Yes

Indoor biofuel burning

No

Yes

OR per 1 year increase in age

*

Author Manuscript

Current co-trimoxazole use

No

Author Manuscript
n

64

27

24

55

60

74

n

--

53%

47%

48%

52%

64%

%

Referent

1.63 (0.72 – 3.69)

Referent

0.90 (0.55 – 1.48)

Referent

Crude OR (95% CI)

Referent

1.72 (0.73 – 4.07)

Referent

0.83 (0.49 – 1.39)

Referent

aOR – adjusted for age, gender and WHO HIV clinical stage (95% CI)

Author Manuscript

No tachypnea (n = 115)

Author Manuscript

Tachypnea (n = 143)
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